Invivyd Appoints Michael Mina as Chief Medical Officer to Advance Infectious Disease Prevention
NEW HAVEN, Conn. – March 6, 2026 – Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer. This strategic move underscores Invivyd’s commitment to advancing infectious disease prevention, particularly in the face of evolving viral threats like COVID-19, Long COVID, RSV, and measles.
A Leading Expert in Infectious Disease
Dr. Mina brings a wealth of experience to Invivyd, having previously served as an assistant professor at the Harvard T.H. Chan School of Public Health, Harvard Medical School, and Brigham and Women’s Hospital Invivyd. His research at Harvard focused on antibodies, vaccines, and infectious diseases, with a particular emphasis on COVID-19 and measles BioSpace. He has also held leadership positions as chief science or chief medical officer at several diagnostics and digital health companies Invivyd.
Expanding Invivyd’s Pipeline of Monoclonal Antibodies
“Dr. Mina joins us at a critical time in American medicine and the evolution of infectious disease prophylaxis,” said Marc Elia, Chairman of the Invivyd Board of Directors PharmaNow. “His unique training and skills, spanning medical training, epidemiology, and basic immunology, combined with a track record of advancing pragmatic solutions to complex problems, can support accelerate our operate as we expand our pipeline of monoclonal antibodies.”
Dr. Mina’s expertise is expected to be a significant asset to Invivyd as the company seeks to provide Americans with more choices in protecting themselves from viral threats PharmaNow. He is a prolific researcher, with over 100 scientific publications and 10,000 citations, and is known for his ability to communicate complex scientific information to a broad audience BioSpace.
Looking Ahead
“Invivyd is at the forefront of advancing infectious disease prevention as the leader in infectious disease monoclonal antibodies,” Dr. Mina stated BioSpace. The company is well-positioned to improve both the treatment and prevention of critical viral diseases.